Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
NLS Pharmaceutics AG (NLSPW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/30/2025: NLSPW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -90% | Avg. Invested days 12 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 37.77M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.04 | 52 Weeks Range 0.00 - 0.06 | Updated Date 05/31/2025 |
52 Weeks Range 0.00 - 0.06 | Updated Date 05/31/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -111.41% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 1687887 |
Shares Outstanding - | Shares Floating 1687887 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
NLS Pharmaceutics AG
Company Overview
History and Background
NLS Pharmaceutics AG, founded in 2015, is a Swiss biopharmaceutical company focusing on developing treatments for attention deficit hyperactivity disorder (ADHD) and other central nervous system (CNS) disorders. Initially focused on researching and acquiring promising drug candidates, NLS Pharmaceutics has since advanced its lead product candidate, Quilience, through clinical development.
Core Business Areas
- Product Development: Focuses on the clinical development and regulatory approval of proprietary product candidates, primarily Quilience (mazindol ER), for ADHD and narcolepsy.
- Commercialization: Plans for commercialization of approved products through strategic partnerships and licensing agreements.
Leadership and Structure
The leadership team consists of experienced pharmaceutical executives and scientists. The organizational structure is typical for a small biotech company, focusing on R&D, clinical development, and business development.
Top Products and Market Share
Key Offerings
- Quilience (Mazindol ER): Quilience is a proprietary extended-release formulation of mazindol, being developed for the treatment of ADHD. It is in phase 2 trials for treatment of ADHD. Market share is N/A at this stage. Key competitors for the treatment of ADHD include stimulants such as Adderall (Teva Pharmaceuticals, NASDAQ:TEVA) and Concerta (Johnson & Johnson, NYSE:JNJ), and non-stimulants such as Strattera (Eli Lilly, NYSE:LLY) and Qelbree (Supernus Pharmaceuticals, NASDAQ:SUPN).
Market Dynamics
Industry Overview
The ADHD market is a large and growing market, driven by increasing awareness and diagnosis rates. However, it is also competitive with many established treatment options.
Positioning
NLS Pharmaceutics AG is positioned as a company developing novel treatments for ADHD with a focus on improved efficacy and safety profiles compared to existing options. Their success hinges on clinical trial results.
Total Addressable Market (TAM)
The global ADHD market is expected to reach approximately $25 billion by 2027. NLS Pharmaceutics AG aims to capture a portion of this market with Quilience, positioning it to compete with established ADHD medications.
Upturn SWOT Analysis
Strengths
- Novel formulation of an existing drug (Mazindol)
- Potential for improved efficacy and safety
- Experienced management team
- Focus on a large and growing market
Weaknesses
- Limited financial resources
- Reliance on clinical trial success
- Competition from established pharmaceutical companies
- Currently has no commercialized product
Opportunities
- Positive clinical trial results
- Strategic partnerships with larger pharmaceutical companies
- Expansion into new markets
- Development of new product candidates
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from generic drugs
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- TEVA
- JNJ
- LLY
- SUPN
Competitive Landscape
NLS Pharmaceutics AG faces significant competition from established pharmaceutical companies with approved ADHD treatments. The company's success depends on demonstrating the superior efficacy and safety of Quilience.
Growth Trajectory and Initiatives
Historical Growth: Historical growth cannot be determined as the data is unavailable.
Future Projections: Future growth is dependent on clinical trial outcomes and regulatory approvals. Analyst estimates unavailable due to limited coverage.
Recent Initiatives: Recent initiatives include advancing Quilience through clinical trials and exploring potential partnerships.
Summary
NLS Pharmaceutics AG is a small biopharmaceutical company focusing on the development of Quilience for ADHD. The company has potential because it has a novel formulation for the treatment of ADHD, but faces risks associated with clinical trials, regulatory approvals, and the market share that is already controlled by other big name pharmaceutical companies. The company needs to achieve positive clinical trial results and secure strategic partnerships to successfully commercialize its products.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
- Third-party financial data providers
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor. Market share data is estimated.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About NLS Pharmaceutics AG
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-01-29 | Co-Founder, CEO & Director Mr. Alexander Zwyer M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://nlspharma.com |
Full time employees - | Website https://nlspharma.com | ||
NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience for the treatment of narcolepsy; and Nolazol for the treatment of ADHD. The company also develops NLS-4, a selective dopamine reuptake inhibitor treatment for the chronic fatigue associated with the symptoms of Long-COVID; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist for improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. It has licensing agreements with Pegasus Advanced Research for use of mazindol for the treatment of ADHD. NLS Pharmaceutics AG was incorporated in 2015 and is headquartered in Zurich, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.